N-(2-[(2-aminoethyl)(methyl)amino]-5-{[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino}phenyl)acetamide

Term ID

CHEBI:143115

Synonyms

AZKi-012a
N-(2-[(2-aminoethyl)(methyl)amino]-5-{[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino}phenyl)acetamide

Definition

A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3, 5, and 7 by cyano, {3-acetamido-4-[(2-aminoethyl)(methyl)amino]phenyl}nitrilo and cyclopropylnitrilo groups, respectively. It is a DYRK2 and CSNK2A2 kinase inhibitor.

References

PDBeChem:5Y3
PMID:26985319
Patent:WO2013144532

Ontology

ChEBI ( EBI )

Relationships

is a type of: acetamides cyclopropanes nitrile pyrazolopyrimidine secondary amino compound ... Show All 7 Terms

acetamides cyclopropanes nitrile pyrazolopyrimidine secondary amino compound substituted aniline tertiary amino compound Show first 5 Terms
has_role: antineoplastic agent EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor

antineoplastic agent EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor Show first 5 Terms

Phenotype

Phenotype resulting from N-(2-[(2-aminoethyl)(methyl)amino]-5-{[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino}phenyl)acetamide

Phenotype where environments contain N-(2-[(2-aminoethyl)(methyl)amino]-5-{[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino}phenyl)acetamide

Phenotype modified by environments containing N-(2-[(2-aminoethyl)(methyl)amino]-5-{[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino}phenyl)acetamide

Human Disease Model